Stryker Co. (NYSE:SYK) Stake Boosted by M&T Bank Corp

M&T Bank Corp grew its stake in shares of Stryker Co. (NYSE:SYK) by 4.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 53,316 shares of the medical technology company’s stock after purchasing an additional 2,496 shares during the quarter. M&T Bank Corp’s holdings in Stryker were worth $19,196,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Kohmann Bosshard Financial Services LLC bought a new position in shares of Stryker during the fourth quarter valued at approximately $25,000. Dunhill Financial LLC grew its holdings in shares of Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares during the last quarter. Centricity Wealth Management LLC bought a new position in shares of Stryker during the fourth quarter valued at approximately $30,000. BankPlus Trust Department bought a new position in shares of Stryker during the fourth quarter valued at approximately $33,000. Finally, Darwin Wealth Management LLC bought a new position in shares of Stryker during the third quarter valued at approximately $36,000. 77.09% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Royal Bank of Canada upped their target price on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. The Goldman Sachs Group raised their target price on Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a research report on Thursday, January 30th. Barclays raised their target price on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. JMP Securities restated a “market perform” rating on shares of Stryker in a research report on Tuesday, February 18th. Finally, Wells Fargo & Company raised their target price on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average price target of $422.15.

Stryker Stock Performance

Shares of NYSE SYK opened at $396.10 on Thursday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $151.14 billion, a price-to-earnings ratio of 51.04, a PEG ratio of 2.93 and a beta of 0.96. The stock’s fifty day simple moving average is $381.96 and its 200 day simple moving average is $372.45. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the business posted $3.46 EPS. As a group, sell-side analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is 43.30%.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.